Chemed (CHE) Non-Current Deffered Revenue (2009 - 2026)

Chemed has reported Non-Current Deffered Revenue for 18 years, with the latest figure at $142.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 12.07% year-over-year to $142.7 million; the trailing twelve-month figure through Mar 2026 stood at $142.7 million (up 12.07% YoY), and the FY2025 full-year result was $136.1 million, up 8.02% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $142.7 million, up from $136.1 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $142.7 million in Q1 2026, with the low at $89.9 million in Q3 2022.
• Average Non-Current Deffered Revenue over 5 years is $113.7 million, with a median of $117.6 million recorded in 2024.
• Year-over-year, Non-Current Deffered Revenue fell 10.49% in 2022 and increased 21.11% in 2024.
• Tracing CHE's Non-Current Deffered Revenue over 5 years: stood at $92.3 million in 2022, then rose by 12.71% to $104.1 million in 2023, then rose by 21.11% to $126.0 million in 2024, then climbed by 8.02% to $136.1 million in 2025, then climbed by 4.79% to $142.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $142.7 million (Q1 2026), $136.1 million (Q4 2025), and $132.4 million (Q3 2025), per Business Quant data.

Peer Comparison